Cordyceps and Improved Karnofsky Performance Status

Safety in these studies

gastrointestinal adverse reactionsNo significant differenceRR: 0.80, 95%CI: 0.47-1.37
gastrointestinal adverse reactions (RR: 0.80, 95%CI: 0.47-1.37, P = 0.42)
from: Adjuvant treatment with Cordyceps sinensis for lung cancer: A systematic review and meta-a
liver and renal damageNo significant differenceRR: 0.32, 95%CI: 0.09-1.10
liver and renal damage (RR: 0.32, 95%CI: 0.09-1.10, P = 0.07)
from: Adjuvant treatment with Cordyceps sinensis for lung cancer: A systematic review and meta-a

1 of 1 paper

Adjuvant treatment with Cordyceps sinensis for lung cancer: A systematic review and meta-analysis of randomized controlled trials.